Fact-checked by Grok 2 weeks ago

Applied Biosystems

Applied Biosystems is an specializing in integrated systems for genetic , including instruments, consumables, reagents, and software primarily used in , (PCR), and quantitative PCR (qPCR) applications. Founded in 1981 as GeneCo (Genetic Systems Company) in , by scientists Sam Eletr and André Marion, the company initially focused on developing biochemical instruments and diagnostic research tools for . Acquired by in 1993 and later spun off as a publicly traded entity in 2000 under the name Applera Corporation's Applied Biosystems group, it merged with in 2008 to form , which was subsequently acquired by in 2014 for $13.6 billion, integrating it as a key within the company's life sciences solutions portfolio. The company's early innovations revolutionized by automating labor-intensive processes, such as the release of its first commercial instrument, the Model 470A automated protein sequencer, in 1982, which enabled efficient determination of sequences in proteins for . A pivotal milestone came in 1986 with the introduction of the ABI 370, the world's first fully automated DNA sequencer based on technology, which significantly accelerated genetic analysis and became a cornerstone for large-scale projects like the (HGP). During the HGP (1990–2003), Applied Biosystems' capillary electrophoresis-based sequencers, including the ABI PRISM models, processed the majority of the sequencing reads, contributing to the project's completion ahead of schedule and under budget by enabling high-throughput data generation. Subsequent advancements included the development of probe-based real-time assays in the 1990s, which allowed for precise quantification of and detection, and the ABI 3730 series sequencers in the early 2000s that supported the draft human genome assembly. As of 2025, under Thermo Fisher Scientific, Applied Biosystems continues to drive precision medicine and genomics research with a portfolio of over 20,000 products, including the QuantStudio qPCR systems for absolute quantification, SeqStudio genetic analyzers for Sanger sequencing, integrated solutions for next-generation sequencing (NGS) workflows, and recent launches such as the MagMAX HMW DNA Kit (2025) and TaqMan QSY2 probes (2024). These tools are widely used in applications ranging from clinical diagnostics and forensic analysis to agricultural biotechnology and cancer research, with notable impacts in identifying genetic markers for over 4,000 human diseases and supporting global initiatives like the 1000 Genomes Project. The brand's emphasis on user-friendly software, such as cloud-based data analysis platforms, sustainable instrument designs, and recent partnerships like the 2025 collaboration with OpenAI for AI-accelerated life science breakthroughs, underscores its ongoing commitment to accessible, reproducible scientific advancements.

Company Overview

Founding and Early Milestones

Applied Biosystems was founded in May 1981 in , by Sam Eletr and André Marion, two engineers formerly with , initially under the name GeneCo before being renamed Applied Biosystems to reflect its focus on developing automated instruments and reagents for protein and analysis. The company's early efforts centered on commercializing technologies for biomolecular , addressing the growing needs of the emerging sector. In August 1982, Applied Biosystems launched its first commercial product, the Model 470A Protein Sequencer, a benchtop instrument that automated the process to identify sequences in proteins, significantly speeding up what had previously been a labor-intensive manual procedure. This was followed in 1983 by the Model 380A DNA Synthesizer, which enabled the automated synthesis of —short DNA strands essential for experiments such as gene cloning and probe design. That same year, the company went public with an initial offering on the exchange under the symbol ABIO, raising funds to support in automated biomolecular instrumentation; revenues reached $5.9 million, up from $402,000 in fiscal 1982. By 1984, sales had tripled to over $18 million, and the company achieved its second annual profit, with employee numbers surpassing 200 amid surging demand from biotech firms for efficient sequencing and synthesis tools. Revenues continued to grow nearly 70% in 1985 to more than $35 million, marking the third consecutive profitable year and solidifying Applied Biosystems' foundational role in .

Current Ownership and Operations

Applied Biosystems operates as a core brand within the Life Sciences Solutions segment of Inc., following the 2008 merger of its parent company with to form Corporation, and 's subsequent $13.6 billion acquisition of in 2014. This integration positioned Applied Biosystems as a key provider of genetic tools under 's global umbrella, which reported total revenues of $42.88 billion in 2024. Headquartered in Waltham, Massachusetts—Thermo Fisher Scientific's corporate base—Applied Biosystems maintains major research and development and manufacturing operations in Foster City, California, with additional facilities spanning Europe, Asia, and the Americas to support international distribution and service. The brand's operational scope centers on delivering end-to-end genetic analysis solutions, serving sectors including academic and applied research, clinical diagnostics, biopharmaceutical development, forensics, and agribusiness. Applied Biosystems contributes to the segment's quarterly revenues of $2.59 billion in Q3 2025. Recent initiatives emphasize advancements in digital and next-generation sequencing workflows, alongside sustainable manufacturing efforts such as the 2025 launch of Plastics Sustain Series, which reduces carbon footprints while upholding performance standards.

Historical Development

Independence and Initial Growth (1981–1993)

Following its in June 1983 at $18 per share, Applied Biosystems operated as an independent listed on under the symbol ABIO, enabling it to fund expansion through equity markets during the burgeoning sector. Michael W. Hunkapiller joined the company in 1983 as a key executive, eventually rising to become its president and CEO, guiding strategic direction amid rapid technological advancements. The corporate structure emphasized innovation in automated , with a focus on scaling manufacturing and distribution to meet growing demand from institutions. The company targeted academic laboratories and emerging firms, achieving significant market penetration in automated by capturing a dominant position as the undisputed leader in the field by the early 1990s. This success stemmed from early products like the Model 470A automated protein sequencer, launched in 1982, which addressed labor-intensive manual processes. Financially, Applied Biosystems turned profitable in 1984, with revenues tripling to $21 million that year from prior levels and surging nearly 70% to over $35 million in 1985, driven by sales of sequencing and instruments. By 1992, annual revenues had grown to $183 million, reflecting robust demand and operational efficiencies. Strategic investments in analysis tools capitalized on the 1980s boom, marked by increased funding for genetic research and the rise of applications. A pivotal move was the 1986 launch of the Model 370A DNA sequencer, which automated fluorescent detection for higher-throughput analysis and solidified the company's pivot toward DNA technologies. However, challenges persisted, including persistent competition from cost-effective manual sequencing methods that remained prevalent in resource-limited labs, as well as early disputes, such as the 1991 against Cruachem Ltd. over reagents for DNA synthesizers. These hurdles tested the company's resolve but underscored its commitment to protecting innovations central to .

Acquisition by Perkin-Elmer and Expansion (1993–2000)

In October 1992, Perkin-Elmer Corporation announced its acquisition of Applied Biosystems Inc. for $330 million in a stock-swap deal, exchanging 0.678 shares of its for each share of Applied Biosystems; the merger was completed in February 1993, forming the Applied Biosystems division as a focused on life sciences . This transaction combined Perkin-Elmer's established expertise in analytical with Applied Biosystems' specialized tools for research, such as DNA synthesizers and sequencers, enabling the new entity to manage Perkin-Elmer's broader life sciences operations. The integration strategy emphasized synergies in product development and market expansion, with Applied Biosystems retaining its name initially while overseeing PCR technologies and targeting growth in applications like forensics, paternity testing, agriculture, and environmental analysis. Following the 1991 acquisition of the Taq polymerase patents by Roche from Cetus, PE Applied Biosystems continued the pre-existing partnership with Roche for Taq DNA polymerase, facilitating its role in the polymerase chain reaction (PCR) market and enhancing its portfolio of genetic analysis tools. This move, combined with Perkin-Elmer's distribution networks, supported joint efforts in R&D to advance automated sequencing and amplification systems, driving diversification beyond core DNA synthesis. By 1998, the division underwent restructuring and was renamed PE Biosystems to reflect its consolidation of life sciences acquisitions, including PerSeptive Biosystems, while separating from Perkin-Elmer's traditional analytical business to prioritize growth. This evolution positioned PE Biosystems as a dedicated life sciences unit, culminating in Perkin-Elmer's 1999 reorganization into PE Corporation to further isolate and expand its biotech operations. Revenue milestones underscored the expansion's impact: the combined entity reported $1.1 billion in total revenues for 1992, with PE Applied Biosystems contributing $653 million by 1997 and reaching $922 million in 1998 through PCR and sequencing demand. By fiscal 2000, the group's revenues grew 21.6% year-over-year to approximately $1.2 billion, reflecting a exceeding 25% in biotech segments from 1993 to 2000, fueled by licensing synergies and .

Spin-off as Applera Corporation (2000–2008)

In 1999, Perkin-Elmer Corporation announced plans to separate its life sciences division from its analytical instruments business, selling the latter to EG&G Inc. while reorganizing the former into PE Corporation as a focused entity on genomics and biotechnology tools. This restructuring culminated in the formation of Applera Corporation in 2000, when PE Corporation changed its name to Applera and adopted a dual-class tracking stock structure; shares traded under the symbols ABI for the Applied Biosystems Group and CEL (initially CRA) for the Celera Genomics Group, allowing investors to track the performance of each business unit separately while maintaining unified corporate governance. Under the leadership of Tony L. White, who served as Applera's Chairman, President, and CEO since 1995, the company emphasized advancements following the integration of Celera Genomics, which had been established in to accelerate the through private-sector sequencing efforts. In 2001, Applera deepened its commitment to these initiatives by shifting Celera's focus from large-scale sequencing to leveraging genomic data for and diagnostics, aligning with broader post-sequencing goals. White's strategy positioned Applera as a key enabler in the revolution, with Applied Biosystems providing instrumentation and reagents to support Celera's data-driven applications. Applera achieved peak revenues of approximately $1.6 billion from the Applied Biosystems Group in fiscal , driven by demand for genetic analysis tools amid the boom. However, the completion of the draft in 2001 triggered a post-genome bubble burst, leading to reduced for and sharp declines in Celera's information services revenue as subscription contracts expired. These challenges contributed to overall financial pressures, with Celera reporting net losses exceeding $200 million in fiscal 2002, and by , the low trading prices of the CEL tracking stock raised concerns about potential delisting from the due to non-compliance with minimum price requirements. To address these headwinds, Applera pivoted toward applied markets such as forensics, environmental testing, and clinical diagnostics, where demand remained stable outside the volatile research sector. In 2003, the company implemented a major plan for the Applied Biosystems Group, incurring pre-tax charges of $33.8 million for benefits affecting approximately 400 employees, asset impairments, and facility closures to streamline operations and cut costs amid economic uncertainty. Applera faced ongoing legal scrutiny related to its , including a filed in August 2001 alleging misleading disclosures in the Celera stock offering during the recapitalization. By 2007, the company reached a settlement in shareholder litigation challenging aspects of the dual-class tracking stock arrangement established in the 1999-2000 reorganization, resolving claims that it disadvantaged certain investors without admitting liability.

Merger with Invitrogen and Thermo Fisher Integration (2008–Present)

In 2008, Corporation acquired Applied Biosystems Inc. for approximately $6.7 billion in a merger that combined the two companies to form Corporation, with Applied Biosystems serving as the primary instrumentation arm focused on genetic analysis tools. The transaction, announced in June and completed on November 21, 2008, aimed to create synergies in life sciences by integrating 's reagents and consumables expertise with Applied Biosystems' sequencing and technologies, resulting in a combined entity with annual revenues of about $3.4 billion and an emphasis on end-to-end workflows for and applied markets. Under , operations expanded to streamline product portfolios and enhance customer integration, with the company maintaining its public status on the under the ticker LIFE following the merger of the two publicly traded entities. The focus shifted toward unified solutions for and , leveraging Applied Biosystems' instruments alongside Invitrogen's reagents to support applications in and diagnostics, while achieving operational efficiencies that contributed to revenue growth in subsequent years. In 2013, Thermo Fisher Scientific announced its acquisition of Life Technologies for $13.6 billion in cash, a deal completed in early 2014 that integrated the latter's portfolio into Thermo Fisher's broader life sciences offerings. The acquisition, finalized on February 4, , absorbed Life Technologies into a new reporting segment called Life Sciences Solutions and positioned Applied Biosystems as a brand within Thermo Fisher, emphasizing its role in high-throughput genetic analysis instruments. This consolidation enhanced Thermo Fisher's capabilities in and clinical applications, with Applied Biosystems' technologies forming a core component of the expanded ecosystem. Following the 2014 integration, Applied Biosystems advanced into cloud-based tools, such as the Applied Biosystems qPCR Analysis Modules introduced on the Thermo Fisher in 2015, enabling remote secondary data processing and integration for real-time workflows. The brand also supported global regulatory approvals for next-generation sequencing (NGS) applications in clinical settings, including expansions of the Oncomine Dx Target Test, which received FDA diagnostic approvals starting in 2017 and further clearances in over 20 countries by 2025 for targeted therapies in . Additionally, Thermo Fisher's 2023 Corporate Social Responsibility Report highlighted sustainability efforts in the , including expanded programs to assess environmental impacts across suppliers supporting Applied Biosystems' . As of 2025, Applied Biosystems continues to drive innovation under without any major divestitures, contributing to the parent company's annual revenue exceeding $40 billion, primarily through the Life Sciences Solutions segment that encompasses its genetic analysis instruments and related technologies. Recent developments include ongoing enhancements in multi-omics tools and strategic investments in U.S. capacity, reinforcing Applied Biosystems' integration into Thermo Fisher's global operations focused on accelerating scientific breakthroughs.

Products and Technologies

Genetic Analysis Instruments

Applied Biosystems offers a range of genetic analysis instruments designed for amplification, , and quantitative , enabling precise genetic research and diagnostics. These tools, integrated into Thermo Fisher's portfolio following the 2008 merger, support workflows from basic thermal cycling to high-throughput and fragment . Key systems emphasize user-friendly interfaces, reliable performance, and compatibility with standardized consumables for applications in research , clinical diagnostics, and forensic . Thermal cyclers form the foundation of PCR-based genetic analysis, with the serving as a core instrument in the lineup. Introduced in the , the VeritiPro features a 96-well format with 0.2 mL alloy blocks and gradient capabilities that allow for precise temperature optimization during protocol development, achieving maximum block ramp rates of 6.0°C/sec. This enables efficient amplification of DNA targets across diverse experimental conditions, such as allele-specific for . Its advanced temperature control and connectivity options, including remote monitoring, enhance reproducibility in research and diagnostic labs. For DNA sequencing, Applied Biosystems provides capillary electrophoresis-based systems, including the ABI PRISM 3730xl DNA Analyzer from the 2000s and the more recent SeqStudio Flex Genetic Analyzer. The 3730xl, a high-throughput platform with 96 capillaries, supports read lengths up to 1,000 bases and processes up to 1.9 million bases per day, making it suitable for large-scale sequencing projects in and detection. In contrast, the SeqStudio Flex, launched in the 2020s, offers flexible throughput with 8- or 24-capillary configurations and 8-dye capability, accommodating up to four 96- or 384-well plates for and fragment analysis, with a daily throughput of approximately 750 samples in forensic applications. These systems deliver gold-standard accuracy for clinical diagnostics, such as variant confirmation and identification. Quantitative PCR (qPCR) platforms from Applied Biosystems enable sensitive detection and quantification of nucleic acids. The QuantStudio series, exemplified by the QuantStudio 5 Real-Time PCR System, supports 384-well blocks for high-density reactions and achieves a limit of detection below 1 copy per reaction, facilitating applications in analysis and detection. Its optical system spans excitation from 450–680 nm and detection from 500–730 nm, allowing multiplexing of up to five targets with minimal cross-talk. This versatility supports scalable workflows in research and diagnostic screening for infectious diseases. Complementing qPCR, digital PCR systems provide absolute quantification without standard curves. The QuantStudio 3D Digital PCR System employs partition-based technology using chips with 20,000 wells to compartmentalize samples, enabling precise counting of target molecules for applications like in clinical diagnostics and rare detection in forensics. Although discontinued in 2023, it remains a notable tool in legacy setups for absolute quantification. Its successor, the QuantStudio Absolute Q Digital PCR System, provides enhanced partition-based absolute quantification using nanoliter wells. Earlier instruments like the Model 370 automated DNA sequencer laid the groundwork for these advancements by introducing fluorescent detection in the 1980s.

Reagents and Consumables

Applied Biosystems provides a range of reagents and consumables optimized for use with its genetic analysis systems, including chemical formulations for amplification, sequencing, and detection, as well as disposable components to ensure reliable performance in PCR and qPCR workflows. These products are engineered for high specificity, sensitivity, and compatibility, supporting applications from gene expression analysis to forensic identification. Recent additions include the MagMAX HMW DNA Kit (launched August 2025) for streamlined manual and automated high molecular weight DNA extraction from various sample types. PCR reagents from Applied Biosystems include TaqMan assays, which are probe-based systems comprising target-specific primers, probes labeled with reporter dyes and quenchers, and master mixes for real-time detection. These assays leverage the 5' activity of to cleave the probe during amplification, enabling quantitative detection of DNA or targets with high specificity through minor groove binder (MGB) non-fluorescent quencher (NFQ) technology that enhances probe binding affinity. assays are designed for near 100% efficiency and are widely used for , , and detection, offering reproducible results across diverse sample types. For , the BigDye Terminator v3.1 Cycle Sequencing Kit utilizes dye-labeled dideoxynucleotides (ddNTPs) in a cycle sequencing reaction, allowing the production of fluorescently terminated DNA fragments for capillary electrophoresis-based readouts. This kit is compatible with templates including plasmids up to 15 kb and supports high-quality sequencing reads typically up to 1000 bases, suitable for various templates, including plasmids and PCR products. It includes ready reaction mix, sequencing buffer, primers, and control DNA, facilitating robust performance in routine and high-throughput sequencing applications. Consumables such as MicroAmp optical tubes and plates are low-binding vessels designed for and qPCR, available in formats including 0.2 mL individual tubes, 8-tube strips, and 96- or 384-well plates with optical clear bottoms for detection. These components minimize sample and while promoting uniform , making them suitable for automated workflows and compatible with systems like the QuantStudio series. Specialized reagent lines include forensic STR kits like the GlobalFiler Amplification Kit, which amplifies 24 loci for human identification, incorporating 10 mini-STR markers under 220 bp and one locus partially exceeding 400 bp to enhance recovery from degraded samples. For reproductive health, panels such as the Ion ReproSeq PGS Kits and PGD-SEQ kits provide reagents for preimplantation , including library preparation and whole-genome amplification components for detecting (PGT-A) and monogenic disorders (PGT-M) in embryos. Additionally, the SwiftArrayStudio Analyzer (launched November 2025) supports advanced multi-omics research workflows. All Applied Biosystems reagents and consumables are produced in facilities certified to ISO 13485 and ISO 9001 standards, with forensic-grade products meeting ISO 18385 for low human DNA contamination. Shelf lives typically extend up to 36 months under recommended storage conditions, such as -20°C for enzymes and mixes, ensuring stability and performance consistency.

Innovations and Contributions

Breakthroughs in DNA Sequencing and Synthesis

Applied Biosystems pioneered automated DNA synthesis with the introduction of the Model 380A DNA Synthesizer in 1983, which utilized phosphoramidite chemistry to produce oligonucleotides efficiently. This instrument automated a four-step cycle per nucleotide addition: detritylation to remove the protecting group, coupling of the phosphoramidite monomer, capping of unreacted chains to prevent elongation errors, and oxidation to stabilize the phosphite triester linkage. The process achieved coupling efficiencies exceeding 99% per step, enabling the reliable synthesis of DNA strands up to 100 bases long in a matter of hours rather than days of manual labor. In DNA sequencing, Applied Biosystems advanced Sanger sequencing through the Model 370A, launched in 1986 as the first commercial fluorescent-based automated sequencer. This instrument employed four spectrally distinct fluorescent dyes attached to dideoxynucleotides, allowing simultaneous detection of all four bases via laser excitation and a charge-coupled device camera, which eliminated the need for radioactive labeling and gel lane separations. By automating fragment separation and base calling on slab gels, the Model 370A reduced sequencing time for 500 bases from weeks of manual processing to a few hours per run, dramatically increasing throughput for genomic research. Applied Biosystems further revolutionized amplification with the GeneAmp PCR System 9600 in the early 1990s, designed for high-throughput applications using 96-well formats and thin-walled reaction tubes. This system leveraged the thermostability of Taq DNA polymerase, which remains active at denaturation temperatures up to 95°C, enabling repeated cycles without enzyme replenishment. Optimized ramp rates and hold times achieved cycle durations under 2 minutes, supporting rapid amplification of target DNA sequences and facilitating the scale-up of for large-scale genetic studies. A major leap in quantitative PCR came with TaqMan technology, introduced by Applied Biosystems in 1996, which integrated fluorogenic probes for real-time monitoring of amplification. These probes featured a reporter fluorophore at the 5' end and a quencher at the 3' end, relying on fluorescence resonance energy transfer () to suppress signal until the probe hybridizes to the target and is cleaved by the 5' nuclease activity of during extension. The resulting increase in normalized reporter signal (ΔRn) allowed precise quantification of starting template concentrations across a of at least 10^5-fold, enabling absolute and relative analysis without post-PCR processing. Applied Biosystems amassed numerous patents, underscoring its dominance in biomolecular automation, including key licensing agreements for foundational technologies like the PCR process covered by U.S. Patent 4,683,195. This patent, originally assigned to Cetus Corporation, described the method for amplifying specific nucleic acid sequences through repeated cycles of denaturation, annealing, and extension, which Applied Biosystems commercialized via instruments and reagents to drive widespread adoption in molecular biology.

Role in Major Scientific Projects

Applied Biosystems' instruments played a pivotal role in the (1990–2003), with the ABI 3700 DNA Analyzer generating the majority of the sequence data used by both public and private efforts, including Celera Genomics, which contributed significantly to the draft sequence. This capillary electrophoresis-based sequencer enabled high-throughput processing essential for assembling the 3-billion-base-pair human genome, accelerating breakthroughs in and . In 1994, ABI sequencers facilitated the discovery of the BRCA1 gene, the first identified genetic factor linked to hereditary breast and , by enabling precise mutation analysis in affected families. This advancement allowed researchers to map and sequence the gene, leading to improved hereditary risk screening and targeted therapies for . Applied Biosystems technologies have been integral to forensic applications, including the identification of victims from the , 2001, attacks through of challenging samples. Their STR amplification kits, such as AmpFlSTR, were among the primary tools for generating profiles compatible with the (CODIS), supporting global criminal investigations and missing persons cases. During the in the 2020s, assays from Applied Biosystems enabled rapid detection, with kits receiving FDA and supporting high-volume testing worldwide. These real-time RT-PCR assays targeted multiple viral genes for reliable diagnostics, facilitating millions of tests and responses. In agricultural , Applied Biosystems tools supported crop improvement efforts, such as the 2009 sequencing of the using Sanger methods, which revealed key for enhancing yield and resilience in this staple crop. In 2024, Applied Biosystems introduced the Axiom BloodGenomiX array, a solution for analyzing over 600,000 markers in blood-related traits, aiding research in , , and genetic disease associations.

Corporate Impact

Market Influence and Revenue Milestones

Applied Biosystems rapidly ascended to market dominance in automated DNA sequencing during the 1990s, establishing a monopoly through its pioneering instruments like the ABI 370, which revolutionized genomic research by enabling high-throughput analysis. This leadership position persisted into the early 2000s, with the company capturing the majority of the commercial market for Sanger sequencing technology amid the Human Genome Project's demands. By the 2020s, as part of Thermo Fisher Scientific, Applied Biosystems maintained a strong foothold in quantitative PCR (qPCR), holding approximately 30-34% of the global qPCR instruments market share, driven by its reliable systems for gene expression and pathogen detection. The company's revenue trajectory reflected its expanding influence, reaching roughly $1.6 billion annually by 2001 following robust quarterly performance, such as $411 million in the second quarter of 2000 alone. Pre-merger with in 2008, Applied Biosystems peaked at $2.36 billion in fiscal 2008 revenues, underscoring its scale in genetic analysis tools and consumables. Post-integration into , these operations contributed to the Life Sciences Solutions segment, which generated approximately $9.6 billion in annual revenue as of 2024, representing a key pillar of the parent's $42.9 billion total sales. In the competitive landscape, Applied Biosystems retained leadership in and qPCR niches against rivals like Illumina, which dominated next-generation sequencing but relied on complementary technologies for targeted applications. This positioning bolstered Thermo Fisher's overall , with the Life Sciences Solutions segment—encompassing Applied Biosystems' portfolio—accounting for about 24% of the company's $205 billion market cap in 2023, based on revenue proportionality. The economic impact extended beyond direct sales, as Applied Biosystems' innovations in and sequencing enabled broader biotech industry expansion, contributing to a sector valued at over $3 trillion in U.S. economic output by 2024 through advancements in and diagnostics. Licensing from PCR-related patents further amplified this, generating significant royalties that supported widespread adoption in and clinical settings. Recent performance highlighted sustained momentum, with the Life Sciences Solutions segment declining 3.4% during 2024 amid market challenges, though averaged 4-5% in key quarters, fueled by rising demand for clinical next-generation sequencing in and infectious disease testing. This uptick aligned with broader segment of 4-5%, positioning the company for continued expansion amid evolving regulatory and therapeutic needs.

Acquisitions and Strategic Partnerships

In 1991, Hoffmann-La Roche acquired the patent rights to (PCR) technology, including , from for $300 million in cash plus potential royalties, establishing a foundational partnership that enabled Applied Biosystems (then under Perkin-Elmer) to commercialize PCR reagents and instruments through an exclusive marketing alliance. This deal positioned Applied Biosystems as the primary distributor of PCR kits and thermal cyclers under 's licensing framework, with Roche collecting royalties on sales that supported ongoing innovation in genetic analysis tools. In 2001, Applera Corporation—the parent company of Applied Biosystems—formed Celera Diagnostics as a with Celera Genomics, integrating high-throughput sequencing data and bioinformatics from Celera with Applied Biosystems' instrumentation to advance applied and diagnostics applications. This collaboration leveraged Celera's genomic datasets alongside Applied Biosystems' sequencing platforms, fostering synergies in target discovery and validation for pharmaceutical research. The 2008 merger of Applied Biosystems with , valued at $6.7 billion, created and integrated Invitrogen's expertise in cell analysis tools, such as fluorescence-based imaging and reagents, with Applied Biosystems' genetic analysis portfolio to enable more comprehensive workflows in molecular and cellular research. This union expanded capabilities in areas like protein detection and , driving operational synergies estimated at $80 million in the first year. Following the acquisition of by for $13.6 billion, Applied Biosystems gained access to Thermo Fisher's established technologies, incorporating advanced and tools into its genetic sequencing ecosystem for integrated multi-omics solutions. This integration enhanced analytical precision in and clinical diagnostics by combining with high-resolution mass spec instrumentation. In July 2024, completed the $3.1 billion acquisition of Olink, a company, further strengthening the Life Sciences Solutions portfolio by integrating Olink's proximity extension assay technology with ' genetic analysis tools to advance multi-omics and applications. Through these strategic moves, evolved from a provider of standalone genetic instruments to a key component of end-to-end scientific workflows, significantly broadening its technological reach and market position within 's life sciences division.

References

  1. [1]
    Applied Biosystems | Thermo Fisher Scientific - US
    We've developed powerful assay design algorithms, optimized master mixes, created intuitive data analysis software, and built smart instrumentation to help ...Missing: key | Show results with:key
  2. [2]
    Company History | Thermo Fisher Scientific - IN
    Applied Biosystems (formerly GeneCo) was founded in 1981 by Sam Eletr and Andre Marion as a biochemical and manufactured diagnostic research instrument ...
  3. [3]
    DEFM14A - SEC.gov
    On November 21, 2008, Invitrogen Corporation, a predecessor company to Life Technologies, completed the acquisition of Applied Biosystems, Inc., and changed the ...
  4. [4]
    Thermo Fisher Scientific Completes Acquisition of Life Technologies ...
    Thermo Fisher acquired Life Technologies for $76.13 per share, creating a new Life Sciences Solutions segment, and Life Tech stock ceased trading.
  5. [5]
    A History of the Human Genome Project | Science
    Applied Biosystems Inc. puts the first automated sequencing machine, based on Hood's technology, on the market. (February) In a pivotal report, the NRC ...Missing: sources | Show results with:sources
  6. [6]
    Notes from a Revolution: Lessons from the Human Genome Project
    The private sector played a significant role in the HGP, including the development by Applied Biosystems Inc. of the automated capillary DNA sequencers that ...
  7. [7]
    [PDF] Learn more at thermofisher.com/applied-biosystems
    With a 40-year history of supporting breakthroughs, Applied Biosystems technologies deliver the complete genomics solutions that help scientists ask—and answer ...
  8. [8]
    Applied Biosystems 40th Anniversary | Thermo Fisher Scientific - US
    Download a timeline of how Applied Biosystems technologies have supported history-defining breakthroughs over the past four decades. Download timeline. 40 ...
  9. [9]
    Twenty-Five Years of Advancing Science - Applied Biosystems
    Dec 27, 2016 · and reports revenues of $402,000. A 470A Protein Sequencer at Chiron Corporation in Emeryville, California Applied Biosystems employs almost 80 ...
  10. [10]
    [PDF] 25 years of Applied Biosystems' Model 470A Protein Sequencer
    Oct 5, 2007 · Applied Biosystems released its first commercial product, the Model 470A Protein ... the first-time revenue of $402,000. Using a Model 470A ...
  11. [11]
    DNA/RNA Synthesizer Model 394
    The first ABI synthesizer, Model 380A, shipped in 1983. This object, Model 394 introduced in 1991, was the second wave of Applied Biosystems's DNA/RNA ...
  12. [12]
    BRIEFS - The New York Times
    * Applied Biosystems Inc., a Foster City, Calif., manufacturer of reagents and biochemicals, filed for an initial public offering of 1.3 million shares, through ...
  13. [13]
    Success in Biotech Depends on Timing
    Oct 3, 2011 · The company had its IPO in June 1983 at $18 a share (considering the 48:1 aggregate stock split that would be $.375 in today's capitalization).
  14. [14]
    The History of PCR | Thermo Fisher Scientific - US
    Taq enzyme's impact on molecular biology became apparent in 1988 when Kary Mullis and the Cetus Corporation commercialized the enzyme for widespread use. With ...
  15. [15]
    Thermo Fisher Scientific to Acquire Life Technologies Corporation
    Apr 15, 2013 · Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share, or approximately $13.6 billion.
  16. [16]
    Applied Biosystems 2025 Company Profile - PitchBook
    Developer of instrument-based systems, consumables, software and services for academic research. The company commercializes technology solutions.
  17. [17]
    Thermo Fisher Scientific Reports Third Quarter 2025 Results
    Oct 22, 2025 · Revenue for the third quarter of 2025 grew 5% to $11.12 billion, versus $10.60 billion in the third quarter of 2024. Organic revenue growth was ...
  18. [18]
    qPCR & dPCR Better Together - Studio of the Future - Scientific Videos
    Aug 19, 2025 · The Applied Biosystems QuantStudio real-time and digital PCR systems combined with Applied Biosystems Taqman chemistry deliver flexibility, ...
  19. [19]
    Achieve lower carbon footprint while maintaining same quality and ...
    Jul 25, 2025 · Introducing PCR Plastics, Sustain Series · Achieve lower carbon footprint while maintaining same quality and performance.
  20. [20]
    Applera - wikidoc
    PE/Applied Biosystems Group's net revenues rose to almost US$1.4 billion. Celera that year made milestone headlines when it announced that it had completed the ...<|control11|><|separator|>
  21. [21]
    Long walk to genomics: History and current approaches to ... - NIH
    Nov 17, 2019 · In the 1990s, Applied Biosystems was the undisputed market leader. In contrast with this earlier monopoly, in the 2000s many companies started ...
  22. [22]
    https://pitchbook.com/profiles/company/41158-27
  23. [23]
    WEAK THIRD QUARTER - Nature
    Applied Biosystems, a leading supplier of auto- mated DNA and protein systems, lost $15.9 million on sales of$183 million in fiscall992.Missing: revenue 1985
  24. [24]
    A brief history of Next Generation Sequencing (NGS)
    Jul 26, 2021 · 1987: Applied Biosystems in the US marketed the first automated sequencing machine, called ABI370. This was a significant advance for ...
  25. [25]
    Applied Biosystems, Inc. v. Cruachem, Ltd., 772 F. Supp. 1458 (D ...
    It filed this action alleging that certain phosphoramidite reagents and DNA synthesizers manufactured and distributed by defendants infringe these patents. The ...Missing: sequencing | Show results with:sequencing
  26. [26]
    COMPANY NEWS; PERKIN-ELMER AND APPLIED BIOSYSTEMS ...
    Oct 7, 1992 · ... valued at $330 million. ... The closing of the merger, expected by early 1993, is subject to approval by shareholders of both companies and by ...
  27. [27]
    Perkin-Elmer to buy Applied Biosystems - UPI Archives
    Oct 6, 1992 · Scientific-instrument concern Perkin- Elmer Corp. announced Tuesday it will buy Applied Biosystems Inc. for $330 million in a stock-swap ...
  28. [28]
    COMPANY NEWS; PERKIN-ELMER COMPLETES DEAL FOR ...
    Feb 19, 1993 · Combined, Perkin-Elmer and Applied Biosystems would have had a total revenue of $1.1 billion for 1992.
  29. [29]
    ROCHE/PERKIN-ELMER TAQ POLYMERASE LICENSING DEAL ...
    Jul 26, 1993 · Roche's PCR patents"; the company's basic PCR patents expire in 2004, while its Taq polymerase patents expire in 2006 and 2009. In addition to ...
  30. [30]
    [PDF] INVITROGEN / APPLIED BIOSYSTEMS - REGULATION (EC) No 139
    Nov 11, 2008 · Applied Biosystems holds a non-exclusive worldwide license for the manufacturing and selling of Taq DNA polymerase from Roche. Invitrogen as ...
  31. [31]
    Justice Department Clears Merger Between PerSeptive BioSystems ...
    Jan 15, 1998 · Perkin-Elmer had revenues of approximately $1.3 billion in fiscal year 1997. NeXstar is a biopharmaceutical company that manufactures ...<|control11|><|separator|>
  32. [32]
    Applied Biosystems - Wikipedia
    The roots of Applied Biosystems trace back to GeneCo (Genetic Systems Company), a pioneer biotechnology company founded in 1981 in Foster City, California.History · PE Applied Biosystems · PE Biosystems · Applera
  33. [33]
    PE Corp. changes name to Applera Corp. - Bioprocess Online
    In 1993, Perkin-Elmer merged with Applied Biosystems Inc., which was founded in Foster City, California in 1981. In 1998, Perkin-Elmer consolidated its premier ...
  34. [34]
    [PDF] APPLERA CORPORATION Annual Report
    Geographically, excluding the net revenues of Tecan for fiscal 1999, the Applied Biosystems group reported revenue growth in all regions for fiscal 2000 ...Missing: 1992 | Show results with:1992
  35. [35]
    PE Biosystems reports earnings jump - San Francisco Business Times
    Jul 27, 2000 · Total net revenues for the group for the fourth quarter increased 21 percent over the year-earlier quarter to $391.8 million. Revenues for ...
  36. [36]
    Man on the run - The Economist
    Feb 15, 2001 · Mr White is head of Applera Corporation, whose two component businesses—Applied Biosystems (ABI) and Celera—lead the genomics revolution ...
  37. [37]
    [PDF] APPLERA CORP (Form: 10-K, Filing Date
    Sep 9, 2004 · driving the Applied Biosystems group's revenue growth, including through the hiring of additional appropriately- skilled employees. As of ...Missing: 1982 | Show results with:1982
  38. [38]
    [PDF] Delisting Order: Applera Corporation - SEC.gov
    Dec 29, 2005 · 01 par value, and Applera Corporation-Celera Genomics Group common stock, $.01 par value, together with rights to purchase series B ...Missing: price low 2006 risk
  39. [39]
    schedule 14a - SEC.gov
    Each non-management director received a restricted stock award of 2,600 shares of Applera-Applied Biosystems stock and 1,000 shares of Applera-Celera stock upon ...
  40. [40]
    Invitrogen to Buy Applied Biosystems for $6.7 Billion
    Jun 13, 2008 · Applied Biosystems, founded in 1981 and based in Foster City, Calif., is bigger than its acquirer, with sales of $2.2 billion in 2007 ...
  41. [41]
    Invitrogen Corporation And Applied Biosystems Complete Merger
    Nov 21, 2008 · The company has historical sales of approximately $3.5 billion, employs 9,500 people, has a presence in more than 100 countries, and ...
  42. [42]
    Invitrogen & Applied Biosystems Merge to Form Life Technologies
    Nov 24, 2008 · On Nov. 21, 2008, Invitrogen Corp. and Applied Biosystems Inc. completed their previously announced merger to form a new company named Life Technologies Corp.
  43. [43]
    Becoming Life Technologies - C&EN - American Chemical Society
    May 18, 2009 · Life Technologies is organized into four technology-based divisions. Its revenues for 2008, again calculated as if the two firms had been one, ...<|separator|>
  44. [44]
    Research Update: Life Technologies Corp. Rating R - S&P Global
    Nov 12, 2010 · The acquisition of ABI in late 2008 more than doubled the revenue base, expanding product offerings to include high-priced research instruments.
  45. [45]
    Life Technologies Corporation Announces Fourth Quarter and Fiscal ...
    This includes $191 million of revenue from its recent acquisition of Applied Biosystems (AB), which closed on November 21, 2008. The closing date of the ...
  46. [46]
    Thermo Fisher Completes Life Tech Acquisition - GenomeWeb
    Feb 4, 2014 · Thermo Fisher Scientific said after the close of the market Monday that it had completed the acquisition of Life Technologies for approximately $13.6 billion.<|separator|>
  47. [47]
    Applied Biosystems qPCR Analysis Modules - Thermo Fisher Scientific
    Applied Biosystems analysis modules are innovative cloud-based secondary data analysis solutions that bring together multiple data sets in one convenient place.
  48. [48]
    Thermo Fisher Receives FDA Approval for NGS-Based Companion ...
    Aug 11, 2025 · The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for ...
  49. [49]
    [PDF] 2023 Corporate Social Responsibility Report - Thermo Fisher
    In 2023, we expanded our supply chain due diligence program beyond the ... in companies of any size—to advance sustainability through global supply chains.
  50. [50]
    Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2024 ...
    Jan 30, 2025 · Revenue for the full year was $42.88 billion in 2024 versus $42.86 billion in 2023. Organic revenue and Core organic revenue growth were flat.
  51. [51]
    Thermo Fisher Scientific Invests to Enhance U.S. Innovation and ...
    Apr 24, 2025 · Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will invest an additional $2 billion in the United States over the next four ...<|separator|>
  52. [52]
    TaqMan Real-Time PCR Assays | Thermo Fisher Scientific - US
    Explore TaqMan products for your qPCR needs, ensuring accurate and reproducible results with our extensive range of TaqMan real-time PCR assays.
  53. [53]
    Applied Biosystems PCR Consumables | Thermo Fisher Scientific - US
    MicroAmp EnduraPlates. For automated and high-throughput PCR workflows ; MicroAmp optical plates. Accurate and consistent PCR and real time PCR results ; MicroAmp ...
  54. [54]
    How TaqMan Assays Work | Thermo Fisher Scientific - US
    Applied Biosystems TaqMan assays consist of target-specific primers and probes, optimized for real-time PCR. The mechanisms are described here.
  55. [55]
    TaqMan Assays - 5 Interesting Facts - Taq Polymerase
    Mar 31, 2022 · TaqMan Assays are designed to work at or near 100% efficiency and use a proprietary probe (MGB-NFQ) to increase specificity.
  56. [56]
    TaqMan Assays qPCR Guarantee | Thermo Fisher Scientific - ES
    TaqMan assays are renowned for their high analytical specificity, reproducibility, sensitivity, and extensive content, making them a widely used choice in ...
  57. [57]
    BigDye™ Terminator v3.1 Cycle Sequencing Kit 100 Reactions
    6–10 day delivery1 x 800 μL tube of BigDye™ Terminator v3.1 Ready Reaction Mix • 1 tube M13 (-21) Primer • 1 tube pREF-BDT™ Control DNA • 2 x 1 mL tubes of 5X Sequencing ...
  58. [58]
    [PDF] BigDye® Terminator v3.1 and v1.1 Cycle Sequencing Kits
    1 Cycle Sequencing Kit is optimized for the majority of DNA sequencing applications. The BigDye®. Terminator v1.1 Cycle Sequencing. Kit, which is based on the ...
  59. [59]
    Sanger Sequencing Support—Getting Started - US
    1 Cycle Sequencing Kit is optimized for shorter fragments and for obtaining sequence close to the primer. The BigDye™ Terminator v3.1 Cycle Sequencing Kit is ...<|separator|>
  60. [60]
    MicroAmp™ Optical 96-Well Reaction Plate 10 Plates | Buy Online
    In stock $86 deliveryContains ten 96-well reaction plates. Will require either caps or full plate cover to seal (not included). May be stored at room temperature.
  61. [61]
    MicroAmp Plates for PCR and qPCR - Thermo Fisher Scientific
    Applied Biosystems MicroAmp plates are specifically designed for PCR and qPCR applications and can improve amplification uniformity of samples to deliver ...
  62. [62]
    MicroAmp™ Optical 8-Tube Strip, 0.2 mL - Thermo Fisher Scientific
    In stock $86 deliveryMicroAmp™ Optical 8-Tube Strip, 0.2 mL ; Catalog number:4316567 ; Promotion:RGLOW25 ; Catalog number 4316567 ; Price (USD). 159.65. Online Exclusive. 168.00. Save ...
  63. [63]
    GlobalFiler™ PCR Amplification Kit 200 Reactions | Buy Online
    In stock $149 deliveryGlobalFiler™ PCR Amplification Kit ; Certificates. SDS ; Promotion:RGLOW25 ; Catalog number 4476135 ; Price (USD). 6,880.00. Each ; No. of Reactions: 200 Reactions.
  64. [64]
    [PDF] GlobalFiler PCR amplification kits - Thermo Fisher Scientific
    The kit includes all 24 loci with only 1 locus partially exceeding 400 base pairs. 10 mini-STR loci lie completely below 220 base pairs and all gender-specific ...
  65. [65]
    Preimplantation Genetic Testing of Monogenic/Single-gene ...
    Each PGD-SEQ kit contains library preparation reagents necessary to enable preimplantation genetic testing for monogenetic/single-gene disorders (PGT-M).
  66. [66]
    Certifications | Thermo Fisher Scientific - US
    The sale, service and support of instrumental systems, applications and consumables used for Life Science, research and applied markets.Missing: shelf | Show results with:shelf
  67. [67]
    Human Identification-Forensic Grade Quality - Thermo Fisher Scientific
    Thermo Fisher Scientific is proud to announce that our manufacturing facilities are ISO 18385–compliant. Take a tour of our Warrington, UK site, and see how ...Missing: shelf | Show results with:shelf
  68. [68]
    [PDF] OEM reagent guide for PCR, qPCR, and reverse transcription
    • High stability—36-month shelf life; remains stable after ... manufacturing practices (cGMPs) with a quality management system certified to ISO 13485:2003.
  69. [69]
    DNA synthesizer: Why the innovation never took off - LinkedIn
    Jul 30, 2018 · The only "success" story from that era was Applied Biosystems, who launched the "380A DNA Synthesizer" in 1983. But a brief look at its ...
  70. [70]
    [PDF] ABI™ 3948 Reference Manual - Thermo Fisher Scientific
    Process. In DNA synthesis, synthesis proceeds as follows: DNA Synthesis Cycle Each cycle of nucleotide addition consists of four steps, which differ depending ...
  71. [71]
    Standard Protocol for Solid-Phase Oligonucleotide Synthesis using ...
    Typically the coupling reaction uses a 20-fold molar excess of activator and a 5-fold molar excess of phosphoramidite with respect to the starting scale of the ...
  72. [72]
    [PDF] Sanger Sequencing Best and Worst Practices - rtsf@msu.edu
    Apr 25, 2024 · In 1986, the. Applied Biosystem's ABI 370A became the first automatic fluorescence-based Sanger sequencing instrument. That first instrument ...
  73. [73]
    History and current approaches to genome sequencing and assembly
    In the 1990s, Applied Biosystems was the undisputed market leader. In contrast with this earlier monopoly, in the 2000s many companies started to offer ...
  74. [74]
    DNA sequencing: bench to bedside and beyond - PubMed Central
    The ABI 370A DNA sequencer appeared very shortly, and was first used to determine the sequence of a gene by Craig Venter and colleagues at NIH (44). At NIH, ...
  75. [75]
    30 Years of Thermal Cycler Innovations #2: Paving the Way for ...
    Apr 18, 2017 · Venter published the first completely sequenced genome of a free-living organism Haemophilus influenza 1 using the GeneAmpTM PCR System 9600.Missing: history date Taq polymerase stability
  76. [76]
    DNA polymerases as useful reagents for biotechnology - NIH
    Due to the heat stability of Taq polymerase, the reaction tube could remain in the incubator after the reaction mixture containing the DNA polymerase was ...
  77. [77]
    Thermal Cycler, PCR, Perkin Elmer, Gene Amp 9600 System
    The Perkin Elmer GeneAmp PCR System 9600 combines integrated instrument design, thin-walled 0.2 mL reaction tubes and a 96-well format to offer greater speed, ...Missing: Applied Biosystems 1990s Taq polymerase
  78. [78]
    Evaluation of dual-labeled fluorescent DNA probe purity versus ...
    Real-time PCR instrumentation has been available since 1996. However, the high cost of dual-labeled FRET probes, resulting from the difficulties encountered ...Missing: original | Show results with:original
  79. [79]
    [PDF] Applied Biosystems Real-Time PCR Systems
    Real-time systems for PCR were improved by the introduction of fluorogenic- labeled probes that use the 5′ nuclease activity of Taq DNA polymerase. The.
  80. [80]
    Real time quantitative PCR - PubMed
    The real-time PCR method has a very large dynamic range of starting target molecule determination (at least five orders of magnitude). Real-time quantitative ...
  81. [81]
    US4683195A - Process for amplifying, detecting, and/or-cloning ...
    The present invention is directed to a process for amplifying and detecting any target nucleic acid sequence contained in a nucleic acid or mixture thereof.
  82. [82]
    The Tools Behind Genomics - The Analytical Scientist
    The Applied Biosystems instrument, the model 3700 DNA sequencer, introduced in 1998, was the most successful and generated the lion's share of the sequence data ...
  83. [83]
    3700 DNA Analyzer | National Museum of American History
    This object is a DNA analyzer used by the Celera Corporation in its effort to be the first to sequence the human genome.
  84. [84]
    Applied Biosystems | Thermo Fisher Scientific - KR
    Applied Biosystems. Where genomics comes together. From the gold-standard technology that helped power the Human Genome Project to the in-house expertise ...
  85. [85]
    BRCA1 and BRCA2: 1994 and beyond - PubMed
    The discovery of the first gene associated with hereditary breast cancer, BRCA1, was anticipated to greatly increase our understanding of both hereditary and ...Missing: Applied Biosystems
  86. [86]
    9/11: A Retrospective Panel Discussion on Disaster Victim ...
    Sep 17, 2021 · 9/11: A Retrospective Panel Discussion on Disaster Victim Identification · Discover the future of DNA sample prep with me, Kayli Carrillo.
  87. [87]
    DNA Amplification | Applied Biosystems - National Institute of Justice
    Aug 25, 2023 · Although other kits were available, Applied Biosystem's AmpFℓSTR® and Promega's PowerPlex® kits were the main kits used during the CODIS STR ...
  88. [88]
    [PDF] TaqPath COVID-19 Combo Kit - Letter of Authorization - FDA
    May 18, 2022 · Emergency use of this test is limited to authorized laboratories. Authorized Laboratories: Testing is limited to laboratories certified under ...
  89. [89]
    TaqMan SARS-CoV-2 2.0 Assays | Thermo Fisher Scientific - US
    TaqMan SARS-CoV-2 2.0 assays offer standard and fast workflows, multiple targets for mutation compensation, and use multiple sample types.
  90. [90]
    The B73 maize genome: complexity, diversity, and dynamics - PubMed
    We report an improved draft nucleotide sequence of the 2.3-gigabase genome of maize, an important crop plant and model for biological research.Missing: Applied Biosystems
  91. [91]
    qPCR Instruments Market Size, Trends & Forecast 2025-2035
    Apr 17, 2025 · Market Share Analysis by Key Players. Company/Organization Name, Estimated Market Share (%). Thermo Fisher Scientific Inc. 30-34%. Bio-Rad ...Missing: 2020s | Show results with:2020s
  92. [92]
    Applied Biosystems Revenue Rockets 20% Despite Currency Effect ...
    ... Applied Biosystems reported Thursday revenues of $411 million in fiscal second quarter 2000, a 22 percent increase over revenues of $335.
  93. [93]
    Applera To Buyback $600 Mln Worth Applied Biosystems Shares ...
    Applera Corp-Applied Biosystems Group (ABI) said it agreed to repurchase $600 million worth of Applied Biosystems common stock from Morgan Stanley (MS).<|control11|><|separator|>
  94. [94]
    Thermo Fisher Scientific Inc (TMO) Q3 2025 Earnings Call Highlights
    Oct 22, 2025 · Life Sciences Solutions Revenue: Increased 8% with 5% organic growth. ... 2025 Revenue Guidance: Raised to $44.1 billion to $44.5 billion ...
  95. [95]
    Leading Companies in the Global DNA Sequencing Market
    Feb 10, 2025 · Applied Biosystems™ – Sanger sequencing and qPCR systems; KingFisher ... Market Share: Approx. 45%; Growth Drivers: High adoption of ...
  96. [96]
    Thermo Fisher Scientific (TMO) - Market capitalization
    As of November 2025 Thermo Fisher Scientific has a market cap of $219.05 Billion USD. This makes Thermo Fisher Scientific the world's 74th most valuable company ...
  97. [97]
    New Report Finds Bioscience Sector Generates Over $3 Trillion for ...
    Dec 2, 2024 · The industry's employment has increased significantly, by nearly 15 percent since 2019, maintaining its long-term growth trend and well ...Missing: Applied Biosystems
  98. [98]
    PATENTS IN GENOMICS AND HUMAN GENETICS - PubMed Central
    Patents on methods and DNA sequences relevant to clinical genetic testing show less evidence of benefits and more evidence of problems and impediments, largely ...
  99. [99]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC1523369/
  100. [100]
    The effects of business practices, licensing, and intellectual property ...
    In June of 1984, Mullis presented a poster showing PCR amplification of the beta-globin gene at the Cetus annual scientific meeting in Monterey, but it was ...
  101. [101]
    Joint Venture Agreement - Applera Corp., Applied Biosystems Group ...
    CELERA DIAGNOSTICS JOINT VENTURE AGREEMENT AS OF APRIL 1, 2001 ... Hunkapiller Title: President CELERA GENOMICS GROUP OF APPLERA CORPORATION By: /s/ J.
  102. [102]
    Applied Biosystems Transfers Its Interest In Celera Diagnostics To ...
    Jan 10, 2006 · Since its formation in 2001, Celera Diagnostics has been held equally by Applera's two business groups, Applied Biosystems Group (NYSE:ABI) ...
  103. [103]
    Press Release dated June 12, 2008 - SEC.gov
    Jun 12, 2008 · Under the terms of the merger agreement, Applera-Applied Biosystems shareholders will receive $38.00 for each share of Applera-Applied ...
  104. [104]
    Invitrogen Shareholders Approve Merger with Applied Biosystems
    Oct 28, 2008 · In addition, Invitrogen remains committed to $80 million cost synergies for year one, $20 million higher than previously communicated. With ...Missing: analysis tools